Sprout’s Female Desire Drug: Size Of Safety Studies Doesn’t Matter To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Flibanserin development can move forward after dispute resolution, but women’s health advocates criticize the delay, charging that FDA has a double standard for female sexual dysfunction drugs.
You may also be interested in...
Flibanserin Risk Management Challenges: Can A REMS Prevent Alcohol Interactions?
FDA seeks advisory committee views on risk of hypotension and syncope with Sprout’s sexual dysfunction drug flibanserin when used alone or in combination with alcohol, and whether these risks outweigh ‘numerically small’ benefits over placebo.
Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
Sprout’s flibanserin resubmission should have an easier time at FDA, as experts backed key aspects of trial design used in flibanserin studies and patients sought treatment options at last year’s workshop on female sexual dysfunction.
Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
Sprout’s flibanserin resubmission should have an easier time at FDA, as experts backed key aspects of trial design used in flibanserin studies and patients sought treatment options at last year’s workshop on female sexual dysfunction.